Seikagaku to Begin Clinical Trials of Injectable Hyaluronic Acid Gel for Knee Osteoarthritis Treatment in US.Tokyo, Japan, July 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Seikagaku, a Tokyo company specializing in the study of intra-articular injection of hyaluronic acid hyaluronic acid: see mucopolysaccharide. Hyaluronic acid A polysaccharide which is an integral part of the gel-like substance of animal connective tissue; it supposedly serves as a lubricant and shock absorbent in the joints. , will begun conducting phase III clinical trials of Gel-200, a new hyaluronic acid gel for intra-articular injection in knee osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. patients, in the US in August. The new gel is expected to have a highly analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs effect with only one shot. In the US, Seikagaku has marketed injectable hyaluronic acid gel under the Supartz brand name since 2001, and currently claims a 20% share of the market. Seikagaku hopes that the new drug will help expand its market share further since it requires just one injection compared with multiple injections required of Supartz. The company will bring the new drug to market within four years. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion